Omniscient Neurotechnology vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Omniscient Neurotechnology (o8t) is the pioneer of clinical connectomics with its FDA-cleared Quicktome brain mapping platform; raised up to $36M Series D led by NRFC ($20M); partnered with Jacobs Institute in 2025.
About
Omniscient Neurotechnology (branded as o8t) is an Australian medical technology company founded in 2019 and headquartered in Sydney. Omniscient is the global pioneer of clinical connectomics — the application of brain network science to patient care. Its flagship product, Quicktome, is the world''s first FDA-cleared medical device to generate detailed maps of brain networks from standard MRI scans using artificial intelligence and machine learning. Neurosurgeons use Quicktome before life-changing brain surgeries to visualize critical functional networks (motor, language, vision, memory) and plan surgical approaches that minimize neurological damage.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.